Combination of statin/vitamin ID and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials.

被引：0
|
作者：
de Velasco, Guillermo
Lora, David
Carretero-Gonzalez, Alberto
Martin Soberon, Maria Cruz
Sepulveda Sanchez, Juan Manuel Manuel
Lorente, David
Castellano, Daniel E.
机构：
[1] Univ Hosp 12 Octubre, Dept Med Oncol, I 12, Madrid, Spain
[2] Hosp 12 Octubre, Madrid, Spain
[3] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Hosp Prov Castellon, Dept Med Oncol, Castellon De La Plana, Spain
[6] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6617
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory post-hoc analysis of COU-AA-302 trial data.
    Pilon, Dominic
    Behl, Ajay S.
    Kamstra, Rhiannon
    Xiao, Yongling
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC).
    Romero, Gustavo Rubio
    Weinstein, Alana
    Friedl, Verena
    Foye, Adam
    Playdle, Denise
    Sabol, Alexis
    Li, Patricia
    Huang, Jiaoti
    Feng, Felix Y.
    Stuart, Joshua M.
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Clinical activity of enzalutamide pre- and post-docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Nadal, Rosa
    Zhang, Zhe
    Raheja, Hitesh
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [24] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Alameddine, Zakaria
    Niazi, Muhammad Rafay Khan
    Rajavel, Anisha
    Behgal, Jai
    Keesari, Praneeth Reddy
    Araji, Ghada
    Mustafa, Ahmad
    Wei, Chapman
    Jahangir, Abdullah
    Terjanian, Terenig O.
    CURRENT ONCOLOGY, 2023, 30 (10) : 9262 - 9275
  • [26] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Brown, Myles
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival
    Denis-Bacelar, Ana M.
    Chittenden, Sarah J.
    Dearnaley, David P.
    Divoli, Antigoni
    O'Sullivan, Joe M.
    McCready, V. Ralph
    Johnson, Bernadette
    Du, Yong
    Flux, Glenn D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (04) : 620 - 629
  • [28] Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies
    Bellmunt, Joaquim
    Kheoh, Thian
    Yu, Margaret K.
    Smith, Matthew R.
    Small, Eric J.
    Mulders, Peter F. A.
    Fizazi, Karim
    Rathkopf, Dana E.
    Saad, Fred
    Scher, Howard I.
    Taplin, Mary-Ellen
    Davis, Ian D.
    Schrijvers, Dirk
    Protheroe, Andrew
    Molina, Arturo
    De Porre, Peter
    Griffin, Thomas W.
    de Bono, Johann S.
    Ryan, Charles J.
    Oudard, Stephane
    EUROPEAN UROLOGY, 2016, 69 (05) : 924 - 932
  • [29] Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival
    Ana M. Denis-Bacelar
    Sarah J. Chittenden
    David P. Dearnaley
    Antigoni Divoli
    Joe M. O’Sullivan
    V. Ralph McCready
    Bernadette Johnson
    Yong Du
    Glenn D. Flux
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 620 - 629
  • [30] IMPROVED SURVIVAL IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) TREATED ON CLINICAL TRIALS
    Pezaro, C.
    Omlin, A. G.
    Mukherji, D.
    Sandhu, S.
    Bianchini, D.
    Cassidy, A. Mulick
    Maier, G.
    Olmos, D.
    Attard, G.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 298 - 298
12345